Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
1. A method for preventing, reducing, or eliminating cardiotoxicity induced by an anticancer agent in a subject, the method comprising: administering to the subject an effective amount of a protective agent prior to or simultaneously with the anticancer agent, thereby preventing, reducing, or eliminating the cardiotoxicity induced by the anticancer agent in the subject, wherein the anticancer agent is an anthracycline or salt thereof, and wherein the protective agent is myricetin.
2. The method of claim 1 , wherein the anticancer agent is administered to the subject simultaneously with the protective agent.
3. The method of claim 2 , wherein the anticancer agent and the protective agent are co-formulated in a composition.
4. The method of claim 1 , wherein the protective agent is administered intravenously.
5. The method of claim 1 , wherein the subject suffers from cancer.
6. The method of claim 5 , wherein the cancer is selected from the group consisting of bladder cancer, bone cancer, brain tumor, breast cancer, esophageal cancer, colorectal cancer, leukemia, liver cancer, lung cancer, lymphoma, myeloma, ovarian cancer, prostate cancer, sarcoma, stomach cancer, and thyroid cancer.
7. The method of claim 1 , further comprising administering a second protective agent prior to or simultaneously with the anticancer agent.
8. The method of claim 7 , wherein the second protective agent is dexrazoxane.
9. The method of claim 1 , wherein the protective agent is administered to the subject at least about 5 minutes before the administration of the anticancer agent.
10. The method of claim 1 , wherein the molar ratio of the protective agent to the anticancer agent is from about 1:1 to about 1000:1, or the weight ratio of the protective agent to the anticancer agent is from about 1:1 to about 1000:1.
11. The method of claim 1 , wherein the anthracycline is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.
12. The method of claim 11 , wherein the anthracycline is doxorubicin.
13. A method for treating cancer in a subject, the method comprising:
(a) administering an effective amount of an anticancer agent to the subject suffering from cancer; and
(b) administering to the subject an effective amount of a protective agent prior to or simultaneously with the anticancer agent;
wherein the protective agent prevents, reduces, or eliminates cardiotoxicity induced by the anticancer agent in the subject;
wherein the anticancer agent is an anthracycline or salt thereof; and
wherein the protective agent is myricetin.
14. The method of claim 13 , wherein the anthracycline is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.
15. The method of claim 14 , wherein the anthracycline is doxorubicin.
16. The method of claim 13 , wherein the cardiotoxicity comprises cardiac tissue damage, electrophysiological dysfunction, contractile dysfunction, mitochondrial toxicity, DNA double strand break in cardiomyocytes, apoptosis, or oxidative stress.
17. The method of claim 13 , wherein the molar ratio of the protective agent to the anticancer agent is from about 1:1 to about 1000:1, or the weight ratio of the protective agent to the anticancer agent is from about 1:1 to about 1000:1.
18. The method of claim 1 , wherein the cardiotoxicity comprises cardiac tissue damage, electrophysiological dysfunction, contractile dysfunction, mitochondrial toxicity, DNA double strand break in cardiomyocytes, apoptosis, or oxidative stress.
19. The method of claim 18 , wherein electrophysiological dysfunction comprises QT prolongation, and contractile dysfunction comprises reduced cardiac ejection fraction (EF) or fractional shortening (FS).
20. The method of claim 16 , wherein electrophysiological dysfunction comprises QT prolongation, and contractile dysfunction comprises reduced cardiac ejection fraction (EF) or fractional shortening (FS).
21. The method of claim 13 , wherein the anticancer agent is administered to the subject simultaneously with the protective agent.
22. The method of claim 13 , wherein the protective agent is administered to the subject at least about 5 minutes before the administration of the anticancer agent.